These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34680409)

  • 21. Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections.
    Bork JT; Heil EL; Berry S; Lopes E; Davé R; Gilliam BL; Amoroso A
    Infect Dis Ther; 2019 Jun; 8(2):171-184. PubMed ID: 31054088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of dalbavancin in plasma and skin blister fluid.
    Nicolau DP; Sun HK; Seltzer E; Buckwalter M; Dowell JA
    J Antimicrob Chemother; 2007 Sep; 60(3):681-4. PubMed ID: 17631507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dalbavancin plasma concentrations in 133 patients: a PK/PD observational study.
    Hervochon C; Hennart B; Leroy AG; Corvec S; Boutoille D; Senneville É; Sotto A; Illes G; Chavanet P; Dubée V; Bleibtreu A; De Carné MC; Talarmin JP; Revest M; Castan B; Bellouard R; Dailly É; Allorge D; Dinh A; Le Turnier P; Gregoire M;
    J Antimicrob Chemother; 2023 Dec; 78(12):2919-2925. PubMed ID: 37864551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.
    Thomas G; Henao-Martínez AF; Franco-Paredes C; Chastain DB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106069. PubMed ID: 32603683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections.
    Cojutti PG; Rinaldi M; Zamparini E; Rossi N; Tedeschi S; Conti M; Pea F; Viale P
    Antimicrob Agents Chemother; 2023 May; 65(5):. PubMed ID: 33649108
    [No Abstract]   [Full Text] [Related]  

  • 26. Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry.
    Zhanel G; Silverman M; Malhotra J; Baxter M; Rahimi R; Irfan N; Girouard G; Dhami R; Kucey M; Stankus V; Schmidt K; Poulin S; Connors W; Tascini C; Walkty A; Karlowsky J
    J Glob Antimicrob Resist; 2024 Jun; 38():154-157. PubMed ID: 38908823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives.
    Andreoni M; Bassetti M; Corrao S; De Rosa FG; Esposito V; Falcone M; Grossi P; Pea F; Petrosillo N; Tascini C; Venditti M; Viale P
    Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1125-1134. PubMed ID: 33682593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
    Gatti M; Andreoni M; Pea F; Viale P
    Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials.
    Gonzalez PL; Rappo U; Mas Casullo V; Akinapelli K; McGregor JS; Nelson J; Nowak M; Puttagunta S; Dunne MW
    Infect Dis Ther; 2021 Mar; 10(1):471-481. PubMed ID: 33515414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Multicentre, Prospective, and Retrospective Registry to Characterize the Use, Effectiveness, and Safety of Dalbavancin in German Clinical Practice.
    Hanses F; Dolff S; Trauth J; Seimetz M; Hagel S
    Antibiotics (Basel); 2022 Apr; 11(5):. PubMed ID: 35625206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
    Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
    Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection in Patients With Obesity or Diabetes: A Subgroup Analysis of Pooled Phase 3 Clinical Trials.
    Riccobene T; Lock J; Lyles RD; Georgiades B; Nowak M; Gonzalez PL; Park J; Rappo U
    Open Forum Infect Dis; 2023 Jun; 10(6):ofad256. PubMed ID: 37305839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A HPLC-DAD method to facilitate large-scale therapeutic drug monitoring of dalbavancin.
    Destere A; Merino D; Bonesso L; Lavrut T; Bernasconni A; Garraffo R; Gérard AO; Drici MD
    J Chromatogr B Analyt Technol Biomed Life Sci; 2023 May; 1222():123694. PubMed ID: 37060815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
    Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
    Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
    Zhanel GG; Esquivel J; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Hink R; Berry L; Schweizer F; Zhanel MA; Bay D; Lagacé-Wiens PRS; Walkty AJ; Lynch JP; Karlowsky JA
    Drugs; 2020 Feb; 80(3):285-313. PubMed ID: 31970713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.
    Dowell JA; Goldstein BP; Buckwalter M; Stogniew M; Damle B
    J Clin Pharmacol; 2008 Sep; 48(9):1063-8. PubMed ID: 18633123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single Intravenous Dose Dalbavancin Pathway for the Treatment of Acute Bacterial Skin and Skin Structure Infections: Considerations for Emergency Department Implementation and Cost Savings.
    LoVecchio F; McCarthy MW; Ye X; Henry AD; Doan QV; Lock JL; Riccobene T; Lyles RD; Talan DA
    J Emerg Med; 2024 Mar; ():. PubMed ID: 38825531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dalbavancin as an alternative to traditional outpatient parenteral antimicrobial therapy for deep gram-positive infections - an observational, retrospective review.
    Bao H; Igwilo-Alaneme R; Sonia F; Cowman K; Kahn M; Nori P
    Ther Adv Infect Dis; 2024; 11():20499361241245523. PubMed ID: 38645297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emergency department care of ABSSSI with dalbavancin infusion, direct discharge, and outpatient telemedicine follow up: a study protocol.
    Durante-Mangoni E; Riccardi A; Guarino M; Cesaro F; Lugarà M; Mascolo S; Morelli L; Natale V; Andreoni M
    J Chemother; 2023 Sep; 35(5):397-403. PubMed ID: 36264157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience.
    Cattaneo D; Fusi M; Colaneri M; Fusetti C; Genovese C; Giorgi R; Matone M; Merli S; Petri F; Gori A
    Antibiotics (Basel); 2023 Dec; 13(1):. PubMed ID: 38247579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.